GSK is paying $10.6 billion in cash to acquire Nuvalent, a precision oncology company with three investigational therapies targeting non-small cell lung cancer. It is the British pharmaceutical giant’s largest acquisition in over a decade, and a clear signal that new CEO Luke Miels is betting the company’s future on cancer treatments.

Nuvalent shareholders will receive $124 per share, a 40% premium over the company’s last closing price of roughly $88.49. Following the announcement on June 9, Nuvalent’s stock surged nearly 39% in premarket trading, essentially pricing in the deal immediately.

What GSK is actually buying

The crown jewels here are two drugs with names that sound like they were generated by a Scrabble tournament: zidesamtinib and neladalkib. Both are currently under active FDA review and could launch by the end of 2026.

A third investigational therapy rounds out the Nuvalent portfolio, giving GSK a trio of late-stage assets in a single transaction.

The deal is expected to close in the third quarter of 2026, pending the usual regulatory approvals.

GSK’s oncology reset under new leadership

The Nuvalent acquisition is GSK’s third major deal of 2026, suggesting that Miels is pursuing an aggressive inorganic growth strategy rather than waiting for internal R&D to deliver results.

What this means for investors

If both drugs receive approval and launch successfully by late 2026 or early 2027, GSK will have instantly transformed its oncology portfolio in NSCLC. If either drug hits a regulatory snag, the calculus changes quickly. A $10.6 billion bet on two drugs under review is concentrated risk, even by pharma standards.

Nuvalent shareholders are the obvious near-term winners here, pocketing a 40% premium in a single day. GSK shareholders, meanwhile, are in a more nuanced position. The acquisition adds meaningful pipeline value, but $10.6 billion in cash is a substantial outlay that needs to generate returns.